Market Research Logo

Bone Fracture - Pipeline Review, H2 2018

Bone Fracture - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H2 2018, provides an overview of the Bone Fracture (Musculosk


Introduction
Global Markets Direct Report Coverage
Bone Fracture - Overview
Bone Fracture - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Fracture - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Fracture - Companies Involved in Therapeutics Development
Biopharm GmbH
Bone Therapeutics SA
Entera Bio Ltd
ethris GmbH
Hemostemix Inc
Kolon TissueGene Inc
Kuros Biosciences AG
Laboratorios SALVAT SA
Novartis AG
Viking Therapeutics Inc
Bone Fracture - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCSVT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-008399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bone Fracture - Dormant Projects
Bone Fracture - Discontinued Products
Bone Fracture - Product Development Milestones
Featured News & Press Releases
Jul 17, 2018: Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bone Fracture, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Bone Fracture - Pipeline by Biopharm GmbH, H2 2018
Bone Fracture - Pipeline by Bone Therapeutics SA, H2 2018
Bone Fracture - Pipeline by Entera Bio Ltd, H2 2018
Bone Fracture - Pipeline by ethris GmbH, H2 2018
Bone Fracture - Pipeline by Hemostemix Inc, H2 2018
Bone Fracture - Pipeline by Kolon TissueGene Inc, H2 2018
Bone Fracture - Pipeline by Kuros Biosciences AG, H2 2018
Bone Fracture - Pipeline by Laboratorios SALVAT SA, H2 2018
Bone Fracture - Pipeline by Novartis AG, H2 2018
Bone Fracture - Pipeline by Viking Therapeutics Inc, H2 2018
Bone Fracture - Dormant Projects, H2 2018
Bone Fracture - Dormant Projects, H2 2018 (Contd..1), H2 2018
Bone Fracture - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Bone Fracture, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report